Presentation is loading. Please wait.

Presentation is loading. Please wait.

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy  Todd.

Similar presentations


Presentation on theme: "Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy  Todd."— Presentation transcript:

1 Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy  Todd A. DeWees, PhD, John Nikitas, BA, Sana Rehman, MD, Jeffrey D. Bradley, MD, Cliff G. Robinson, MD, Michael C. Roach, MD  Practical Radiation Oncology  Volume 9, Issue 1, Pages e83-e89 (January 2019) DOI: /j.prro Copyright © 2018 American Society for Radiation Oncology Terms and Conditions

2 Figure 1 Kaplan-Meier overall survival curves of statistically significant cut-points of age-adjusted Charlson comorbidity index. Patients can be divided into 3 groups with age-adjusted Charlson Comorbidity Index ≤5, 6 to 7, and ≥8. Practical Radiation Oncology 2019 9, e83-e89DOI: ( /j.prro ) Copyright © 2018 American Society for Radiation Oncology Terms and Conditions


Download ppt "Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy  Todd."

Similar presentations


Ads by Google